uniQure N.V.
$41.81▼ 7.44%($-3.36)
TickerSpark Score
60/100
▌ Mixed
20
Valuation
40
Profitability
55
Growth
84
Health
100
Momentum
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a QURE research report →
52-Week Range53% of range
Low
$8.73
Current
$41.81
High
$71.50
Company Overviewwww.uniqure.com
About the company
uniQure N. V. develops treatments for patients suffering from rare and other devastating diseases in the United States.
- CEO
- Matthew Kapusta
- IPO
- 2014
- Employees
- 221
- HQ
- Amsterdam, NH, NL
Price Chart
+192.79% · this period
Valuation
- Market Cap
- $2.84B
- P/E
- -11.91
- P/S
- 157.17
- P/B
- 17.57
- EV/EBITDA
- -21.43
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 74.14%
- Op Margin
- -1057.48%
- Net Margin
- -1154.42%
- ROE
- -145.81%
- ROIC
- -26.48%
Growth & Income
- Revenue
- $16.10M · -40.64%
- Net Income
- $-198,971,000 · 16.94%
- EPS
- $-3.46 · 29.67%
- Op Income
- $-187,827,000
- FCF YoY
- 4.37%
Performance & Tape
- 52W High
- $71.50
- 52W Low
- $8.73
- 50D MA
- $29.44
- 200D MA
- $28.86
- Beta
- 0.90
- Avg Volume
- 2.20M
Get TickerSpark's AI analysis on QURE
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Form 4 · Filings
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jun 30, 26 | Abi-Saab Walid | other | 10,000 |
| Jun 30, 26 | Abi-Saab Walid | sell | 10,000 |
| Jun 30, 26 | Abi-Saab Walid | sell | 20,000 |
| Jun 30, 26 | Abi-Saab Walid | other | 10,000 |
| Jun 30, 26 | Kaye Jack | other | 17,060 |
| Jun 30, 26 | Kaye Jack | other | 4,107 |
| Jun 30, 26 | Kaye Jack | sell | 4,107 |
| Jun 30, 26 | Kaye Jack | sell | 17,060 |
| Jun 30, 26 | Kaye Jack | other | 17,060 |
| Jun 30, 26 | Kaye Jack | other | 4,107 |
Coverage · QURE
Our QURE coverage
Recent articles, reports, and earnings notes.
On-Demand Research
No research on QURE yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate QURE report →Internal Compare
Similar companies
Peers in the same neighborhood.
VRDN▲4.98%
Viridian Therapeutics, Inc.
$19.40
GPCR▲2.55%
Structure Therapeutics Inc.
$53.45
EWTX▲1.05%
Edgewise Therapeutics, Inc.
$39.56
OCUL▲1.80%
Ocular Therapeutix, Inc.
$9.64
GLPG▲1.71%
Galapagos N.V.
$27.98
VERA▼3.42%
Vera Therapeutics, Inc.
$41.20
NUVB▲5.17%
Nuvation Bio Inc.
$5.70
CLDX▲4.32%
Celldex Therapeutics, Inc.
$38.37